Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer

Naohiro Okano¹, Tomonori Mizutani², Fumio Nagashima², Junji Furuse²

Affiliations

¹ Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Tokyo 181-8611, Japan. Electronic address: naohiro-okano@ks.kyorin-u.ac.jp.
² Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Tokyo 181-8611, Japan.

PMID: 34592184
DOI: 10.1016/S1470-2045(21)00489-7

Comment

Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer

Naohiro Okano et al. Lancet Oncol. 2021 Oct.

. 2021 Oct;22(10):e423.

doi: 10.1016/S1470-2045(21)00489-7.

Authors

Naohiro Okano¹, Tomonori Mizutani², Fumio Nagashima², Junji Furuse²

Affiliations

¹ Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Tokyo 181-8611, Japan. Electronic address: naohiro-okano@ks.kyorin-u.ac.jp.
² Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Tokyo 181-8611, Japan.

PMID: 34592184
DOI: 10.1016/S1470-2045(21)00489-7

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer - Authors' reply.
Zhu X, Cao Y, Zhang H. Zhu X, et al. Lancet Oncol. 2021 Oct;22(10):e424. doi: 10.1016/S1470-2045(21)00529-5. Lancet Oncol. 2021. PMID: 34592185 No abstract available.

Comment on

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H. Zhu X, et al. Lancet Oncol. 2021 Aug;22(8):1093-1102. doi: 10.1016/S1470-2045(21)00286-2. Epub 2021 Jul 5. Lancet Oncol. 2021. Retraction in: Lancet Oncol. 2022 Mar;23(3):330. doi: 10.1016/S1470-2045(22)00064-X. PMID: 34237249 Retracted. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer

Affiliations

Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical